[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:malignant-peripheral-nerve-sheath-tumor":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":114,"states":119},"Malignant Peripheral Nerve Sheath Tumor",17,[7,15,22,29,35,41,48,54,60,66,72,78,84,90,96,102,108],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04872543","A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)",[11],"Phase 2","RECRUITING","2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.739275Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07549022","Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor",[19],"Phase 1\u002FPhase 2","2026-08-26T02:18:46.137046Z","2026-05-05T02:43:28.649683Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT06693284","A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]",[26],"Early Phase 1","2026-08-26T02:19:02.550788Z","2026-05-05T02:43:27.752468Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT06735820","Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST",[19],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:28.869744Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT05985161","A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors",[11],"2026-08-26T02:15:51.395565Z","2026-05-05T02:43:28.556798Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":46,"content_modified":47},"NCT06041516","A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors",[45],"Phase 1","2026-08-26T02:17:22.949982Z","2026-05-05T02:35:31.780901Z",{"nct_id":49,"title":50,"phases":51,"status":12,"updated_at":52,"content_modified":53},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[19],"2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":55,"title":56,"phases":57,"status":12,"updated_at":58,"content_modified":59},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[19],"2026-08-26T02:19:04.543908Z","2026-07-05T03:45:20.453806Z",{"nct_id":61,"title":62,"phases":63,"status":12,"updated_at":64,"content_modified":65},"NCT04897321","B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",[45],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.511090Z",{"nct_id":67,"title":68,"phases":69,"status":12,"updated_at":70,"content_modified":71},"NCT05732831","Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors",[19],"2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.947953Z",{"nct_id":73,"title":74,"phases":75,"status":12,"updated_at":76,"content_modified":77},"NCT02390752","Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...",[45],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:27.488578Z",{"nct_id":79,"title":80,"phases":81,"status":12,"updated_at":82,"content_modified":83},"NCT05253131","Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas",[11],"2026-08-26T02:15:37.042762Z","2026-05-05T02:43:27.251035Z",{"nct_id":85,"title":86,"phases":87,"status":12,"updated_at":88,"content_modified":89},"NCT05642455","SPEARHEAD-3 Pediatric Study",[19],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:26.852369Z",{"nct_id":91,"title":92,"phases":93,"status":12,"updated_at":94,"content_modified":95},"NCT05245500","Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion",[45],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:26.709142Z",{"nct_id":97,"title":98,"phases":99,"status":12,"updated_at":100,"content_modified":101},"NCT07298083","DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins",[],"2026-08-26T02:19:07.104270Z","2026-05-13T02:55:06.684379Z",{"nct_id":103,"title":104,"phases":105,"status":12,"updated_at":106,"content_modified":107},"NCT03141021","Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors",[],"2026-08-26T02:15:48.613507Z","2026-05-13T02:55:06.108734Z",{"nct_id":109,"title":110,"phases":111,"status":12,"updated_at":112,"content_modified":113},"NCT06515860","Neurofibromatosis Type 1 Tumor Early Detection Study",[],"2026-08-03T02:47:17.144574Z","2026-05-13T02:55:06.496843Z",[115],{"biomarker":116,"count":117,"slug":118},"MTAP Gene",3,"mtap-gene",[120,124,128,132,136,139,142,145,148,151,154,157],{"state":121,"count":122,"slug":123},"Massachusetts",7,"massachusetts",{"state":125,"count":126,"slug":127},"New York",6,"new-york",{"state":129,"count":130,"slug":131},"Texas",5,"texas",{"state":133,"count":134,"slug":135},"Florida",4,"florida",{"state":137,"count":134,"slug":138},"Illinois","illinois",{"state":140,"count":134,"slug":141},"Maryland","maryland",{"state":143,"count":134,"slug":144},"Missouri","missouri",{"state":146,"count":134,"slug":147},"Ohio","ohio",{"state":149,"count":134,"slug":150},"Tennessee","tennessee",{"state":152,"count":117,"slug":153},"California","california",{"state":155,"count":117,"slug":156},"Minnesota","minnesota",{"state":158,"count":117,"slug":159},"New Jersey","new-jersey"]